Gordon Campbell | Parliament TV | Parliament Today | News Video | Crime | Employers | Housing | Immigration | Legal | Local Govt. | Maori | Welfare | Unions | Youth | Search

 


Hospital Supply in Jeopardy as negotiations stall

AstraZeneca Media Statement

31 July 2007

Hospital Supply in Jeopardy as Betaloc® CR and Plendil® negotiations stall

PHARMAC’s decision to issue a media statement about the ongoing negotiations with AstraZeneca over Betaloc CR and Plendil ER has confirmed AstraZeneca’s fear that negotiations with PHARMAC have broken down.

Three years ago AstraZeneca negotiated fixed term supply agreements for Betaloc CR and Plendil ER at price levels that are significantly lower than those offered in other markets (40 to 70 percent lower than other established markets). The fixed terms for Plendil ER and Betaloc CR ended on 30 June this year.

For six months AstraZeneca has been trying to negotiate a new agreement that would ensure the long term supply of Betaloc CR and Plendil for New Zealand cardiovascular patients.

Throughout the process AstraZeneca has remained committed to negotiating a successful outcome for patients. As late as 28 June AstraZeneca made an alternative proposal for the supply of a bundle of products, including Betaloc CR and Plendil ER. This proposal:

• ensures PHARMAC makes savings equivalent to the savings it would make by introducing a generic version of Betaloc CR

• gives long term commercial certainty for AstraZeneca

• creates an environment where AstraZeneca and the supplier of the generic version of Betaloc can compete fairly for market share

• creates a more certain scenario for the patient, with certainty of the same medicine.

AstraZeneca’s first indication that negotiations had stalled came when PHARMAC chose not to formally respond to the latest bundled offer and instead sent a letter to doctors on 18 July stating that further negotiations are unlikely to achieve a result. This fear was confirmed last night when PHARMAC issued a media release accusing AstraZeneca of anti-competitive behaviour.

AstraZeneca remains happy to compete with generic suppliers of Pharmaceuticals on a level playing field and does so in a number of therapeutic areas. PHARMAC’s decision to offer a supplier of a generic version of Betaloc a long term agreement but not continue negotiations with AstraZeneca is not consistent with a competitive market.

Therefore, despite its commitment to continue negotiating, AstraZeneca has been forced to consider the commercial implications of PHARMAC’s decision.

A loss of ability to compete against a generic supplier for the majority of the Betaloc business – Betaloc CR – risks the supply of the low price/low volume service item Betaloc IV. PHARMAC has been repeatedly informed, as early as December 2003 and as recently as 23 May 2007, that loss of the Betaloc CR tablet business to a generic competitor would jeopardise supply of Betaloc IV. It is estimated that current stocks of Betaloc IV will be exhausted by the end of August 2007 at the latest.

AstraZeneca remains committed to a successful negotiated resolution to the current solution regarding Betaloc and Plendil ER.

Betaloc IV is used in the initial 24-48 hours post-heart attack period to stabilise the heart or to quickly bring down the heart rate in cases of arrhythmias (irregular heart beats). In an injectable form the medication penetrates quickly in the blood stream & produces its protective effect on the heart faster than with a tablet. This speed is critical in patients suffering from a heart attack. Approximately 3500 patients use Betaloc IV annually.

Ends

For more information please contact Daniel Herd, 09 354 0577 or 027 694 3574

Summary of Products

Betaloc belongs to a group of medicines called beta-blockers. It works by affecting the body's response to some nerve impulses, especially in the heart. As a result, it decreases the heart's need for blood and oxygen and therefore reduces the amount of work the heart has to do. It also widens the blood vessels in the body, as well as helping the heart to beat more regularly.

Betaloc CR tablets1

(Metoprolol succinate controlled release tablets)

Betaloc CR is a controlled release tablet that releases its drug content in a time controlled manner. Controlled release tablets ensure a more even effect over 24 hours.

Betaloc CR tablets are used for:

• lowering high blood pressure, also called hypertension, and to reduce the risk of complications due to high blood pressure such as stroke, heart attack or early death.

• preventing angina (heart or chest pain brought on by stress or exercise in patients with coronary heart disease).

• treating or preventing heart attacks, or to reduce your risk of heart complications following a heart attack.

• treating heart failure (symptomatic mild to severe chronic heart failure in addition to other heart failure medicine), to help increase survival, reduce hospitalisation, improve symptoms, and Quality of Life.

• treating disturbances of heart rate in patients with heart disease, especially rapid heart beat.

• treating symptoms of rapid or irregular heart beat in patients without heart disease.

Betaloc IV2

(Metoprolol tartrate 1 mg/mL injection)

Betaloc IV is approved for use in:

• Cardiac arrhythmias, especially supraventricular tachycardia, reduction of ventricular rate in atrial fibrillation and ventricular extrasystoles.

• Suspected or definite myocardial infarction.

Plendil ER tablets3

(Felodipine tablets)

Plendil ER belongs to a family of medicines called calcium channel blockers. These medicines do not change the way that the body takes in calcium from food.

Plendil ER works by dilating (expanding) small blood vessels, so that blood can be pumped around the body more easily. It has no negative affect on heart function.

The ER in Plendil ER stands for Extended Release. This means that the tablets are designed to work over a 24 hour period

Plendil ER is used to treat high blood pressure (hypertension) and heart and chest pain brought on, for example, by exercise or stress (known as angina pectoris).

ends


© Scoop Media

 
 
 
 
 
Parliament Headlines | Politics Headlines | Regional Headlines

Digital Evolution: Scoop Independent News Launches "Operation Chrysalis"

From today Scoop is beginning a process of public consultation with the political, business and civil society groups it has served for the past 15 and a half years.

"It is hoped that in time - with new leadership and increased community engagement - the chrysalis will incubate a new kind of Scoop, one which can sustainably continue Scoop's Mission 'to be an agent of positive change'", says Scoop Founder, Editor and Publisher Alastair Thompson.

"As big publishing shrivels, public participation in contributing and spreading news has grown. Scoop has evolved with this wave by providing an independent platform, committed to upholding democracy, providing a voice to all, and providing the public easy access to information about decisions which affect them." More>>

 

Parliament Adjourns:

Greens: CAA Airport Door Report Conflicts With Brownlee’s Claims

The heavily redacted report into the incident shows conflicting versions of events as told by Gerry Brownlee and the Christchurch airport security staff. The report disputes Brownlee’s claim that he was allowed through, and states that he instead pushed his way through. More>>

ALSO:

TAIC: Final Report On Grounding Of MV Rena

Factors that directly contributed to the grounding included the crew:
- not following standard good practice for planning and executing the voyage
- not following standard good practice for navigation watchkeeping
- not following standard good practice when taking over control of the ship. More>>

ALSO:

Gordon Campbell:
On The Pakistan Schoolchildren Killings

The slaughter of the children in Pakistan is incomprehensibly awful. On the side, it has thrown a spotlight onto something that’s become a pop cultural meme. Fans of the Homeland TV series will be well aware of the collusion between sections of the Pakistan military/security establishment on one hand and sections of the Taliban of the other… More>>

ALSO:

Werewolf Satire:
The Politician’s Song

am a perfect picture of the modern politic-i-an:
I don’t precisely have a plan so much as an ambition;
‘Say what will sound most pleasant to the public’ is my main dictum:
And when in doubt attack someone who already is a victim More>>

ALSO:

Flight: Review Into Phillip Smith’s Escape Submitted To Government

The review follows an earlier operational review by the Department of Corrections and interim measures put in place by the Department shortly after prisoner Smith’s escape, and will inform the Government Inquiry currently underway. More>>

ALSO:

Intelligence: Inspector-General Accepts Apology For Leak Of Report

The Inspector-General of Intelligence and Security, Cheryl Gwyn, has accepted an unreserved apology from Hon Phil Goff MP for disclosing some of the contents of her recent Report into the Release of Information by the NZSIS in July and August 2011 to media prior to its publication. The Inspector-General will not take the matter any further. More>>

ALSO:

Drink: Alcohol Advertising Report Released

The report of the Ministerial Forum on Alcohol Advertising and Sponsorship has been released today, with Ministers noting that further work will be required on the feasibility and impact of the proposals. More>>

ALSO:

Other Report:

Leaked Cabinet Papers: Treasury Calls For Health Cuts

Leaked Cabinet papers that show that Government has been advised to cut the health budget by around $200 million is ringing alarm bells throughout the nursing and midwifery community. More>>

ALSO:

Get More From Scoop

 

LATEST HEADLINES

 
 
 
 
 
 
 
 
Politics
Search Scoop  
 
 
Powered by Vodafone
NZ independent news